Clinical trials: Tear Film Deficiency
Dry Eye Syndrome
The Effect of Manuka Eye Drops on Tear Film Properties
Traditionally, Manuka honey has been used to combat against bacteria and reduce inflammation (the body's way of reacting to infection, irritation or other injury).
- Trial name
- NCT03622619
- Testing
- Optimel Antibacterial Manuka+ Dry Eye Drops, Systane Ultra Lubricating Eye Drops
- Where
- Australia
- Volunteers
- 46 people
- Sponsor
- The University of New South Wales
Dry Eye
Digital Device Users Who Are Treated With Systane Hydration PF
Systane Hydration PF is a recently released preservative-free artificial tear that is able to supplement the ocular surface's moisture while simultaneously soothing the eye.
- Trial name
- NCT04837807
- Testing
- Systane Hydration PF
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- University of Alabama at Birmingham
Dry Eye Syndromes
Topical Ophthalmic AGN-195263 for the Treatment of Evaporative Dry Eye
The objectives of this study are twofold To evaluate the safety and efficacy of 0.1% AGN-195263 administered twice daily compared to its vehicle in patients with evaporative dry eye (EDE) To evaluate the systemic pharmacokinetics…
- Trial name
- NCT02815293
- Testing
- AGN-195263, Vehicle
- Where
- 29 sites in United States
- Volunteers
- 36 people
- Sponsor
- Allergan
Meibomian Gland Dysfunction, Dry Eye Syndromes
to Evaluate the Effectiveness and Safety of the Tixel® , VS LipiFlow® in the Treatment of Meibomian Gland Dysfunction
A Randomized, Masked (Evaluator), Controlled, Prospective Study Evaluating the Effectiveness and Safety of the Tixel® Medical Device, Versus LipiFlow® in the Treatment of Meibomian Gland Dysfunction
- Conditions
- Meibomian Gland Dysfunction, Dry Eye Syndromes, Dry Eye
- Trial name
- NCT05162261
- Testing
- Tixel C, LipiFlow
- Where
- 5 sites in United States
- Volunteers
- 109 people
- Sponsor
- Novoxel Ltd.
Dry Eye Syndromes
Safety and Efficacy Study of Cyclosporine Ophthalmic Emulsion in Post-LASIK Patients
This study will evaluate the safety and efficacy of cyclosporine ophthalmic emulsion administered twice daily following LASIK surgery
- Trial name
- NCT00611403
- Testing
- Cyclosporine Ophthalmic Emulsion 0.05% (RESTASIS®), Artificial Tears REFRESH ENDURA®
- Where
- United States
- Volunteers
- 137 people
- Sponsor
- Allergan
Dry Eye
A Study to Assess Efficacy and Safety of HL036 in Subjects With Dry Eyes
The objective of this study was to compare the safety and efficacy of 0.25% HL036 Ophthalmic Solutions to placebo for the treatment of the signs and symptoms of dry eye.
- Trial name
- VELOS-2 (NCT03846453)
- Testing
- HL036 Ophthalmic Solution
- Where
- 12 sites in United States
- Volunteers
- 637 people
- Sponsor
- HanAll BioPharma Co., Ltd.
Dry Eye Syndromes
An Observational Study of Dry Eye Prior to Laser-Assisted in Situ Keratomileusis (LASIK) Therapy
This is an observational, study of dry eye in patients at the consultation visit prior to LASIK surgery. There is no treatment administered or intervention during the study.
- Trial name
- NCT01854905
- Testing
- No Treatment
- Where
- Russia
- Volunteers
- 400 people
- Sponsor
- Allergan
Dry Eye Disease
Study of ST-100 as Treatment for Dry Eye Disease
The objective of this study is to compare the safety and efficacy of two different concentrations of ST-100 Ophthalmic Solution to placebo (vehicle) for the treatment of the signs and symptoms of dry eye.
- Trial name
- NCT05241470
- Testing
- ST-100 Ophthalmic Solution
- Where
- 3 sites in United States
- Volunteers
- 160 people
- Sponsor
- Stuart Therapeutics, Inc.
Dry Eye
Phase II Clinical Study to Evaluate the Efficacy of Multidose Lagricel® Ofteno Ophthalmic Solution as Treatment for Dry Eye Disease.
Phase II, comparative, controlled, multicenter, parallel group, open, randomized clinical study. The main outcome variable will be the Ocular Surface Disease Index (OSDI) questionnaire.
- Trial name
- PRO-037 (NCT04704531)
- Testing
- Sodium Hyaluronate Ophthalmic 0.4% one drop twice a day (BID), Sodium Hyaluronate Ophthalmic 0.4% one drop four times a day (QID), Sodium Hyaluronate Ophthalmic 0.4% Six times per day
- Where
- Mexico
- Volunteers
- 141 people
- Sponsor
- Laboratorios Sophia S.A de C.V.
Dry Eye Disease
Study to Evaluate Safety and Efficacy of Cenegermin (Oxervate®) vs Vehicle in Severe Sjogren's Dry Eye Disease
Primary Objectives: To compare the efficacy of cenegermin vs vehicle in Schirmer I test (without anaesthesia) > 10 mm/5 min at Week 4 by testing the superiority.
- Trial name
- PROTEGO-2 (NCT05136170)
- Testing
- Cenegermin, Vehicle
- Where
- 10 sites in United States, Italy
- Volunteers
- 85 people
- Sponsor
- Dompé Farmaceutici S.p.A
Dry Eye Disease, Dry Eye Syndrome
Safety, PK and Efficacy Study of SJP-0132 in Subjects With Dry Eye Disease
This is the first study in humans to evaluate the effectiveness of SJP-0132 in the treatment of dry eye disease. This study will evaluate the safety, tolerability, efficacy, and pharmacokinetics of single- and multiple-dose…
- Trial name
- NCT04139122
- Testing
- SJP-0132
- Where
- United States
- Volunteers
- 89 people
- Sponsor
- Senju Pharmaceutical Co., Ltd.
Dry Eye
The Effects of Cyclosporin A in a Low Humidity Environment, on the Ocular Surface
This study will test that hypothesis that topical administration of the FDA approved immunomodulatory agent cyclosporin A emulsion will minimize irritation and ocular surface disease that results from a short term low humidity…
- Trial name
- CsA (NCT02199964)
- Testing
- Cyclosporin 0.05% emulsion, Endura, Refresh artificial tears
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Baylor College of Medicine
Dry Eye
Dry Eye Assessment and Management Study
The objective of the DREAM study is to evaluate the effectiveness and safety of supplementation with omega-3 fatty acids in relieving the symptoms of moderate to severe dry eye disease.
- Trial name
- DREAM (NCT02128763)
- Testing
- Omega-3 supplements
- Where
- 27 sites in United States
- Volunteers
- 535 people
- Sponsor
- University of Pennsylvania
Leukodystrophy, White Matter Disease
LeukoSEQ: Whole Genome Sequencing as a First-Line Diagnostic Tool for Leukodystrophies
Leukodystrophies, and other heritable disorders of the white matter of the brain, were previously resistant to genetic characterization, largely due to the extreme genetic heterogeneity of molecular causes.
- Conditions
- Leukodystrophy, White Matter Disease, 4H Syndrome, Adrenoleukodystrophy
- Trial name
- NCT02699190
- Where
- United States
- Volunteers
- 236 people
- Sponsor
- Children's Hospital of Philadelphia
Dry Eye Syndrome
Safety and Efficacy of TOP1630 for Dry Eye Syndrome
In subjects with Dry Eye Syndrome: The primary objective of this study is to compare the safety and tolerability of TOP1630 Ophthalmic Solution to placebo.
- Trial name
- NCT03088605
- Testing
- TOP1630 Ophthalmic Solution
- Where
- United States
- Volunteers
- 69 people
- Sponsor
- ORA, Inc.
Evaporative Dry Eye
Comparison of Tear Evaporation Rate With DAILIES TOTAL1 and Biotrue ONEday
The purpose of this pilot study is to compare the effect of DAILIES TOTAL1, a low water content silicone hydrogel lens, and Biotrue ONEday, a high water content hydrogel lens, on the rate of tear evaporation.
- Trial name
- MALTESE (NCT04037969)
- Testing
- Nesofilcon A, Delefilcon A
- Where
- Canada
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- University of Waterloo
Dry Eye Syndrome
Safety and Efficacy of BRM421 for Dry Eye Syndrome
The objective of this study is to compare the safety and efficacy of BRM421 Ophthalmic Solution to placebo for the treatment of the signs and symptoms of dry eye.
- Trial name
- NCT03066219
- Testing
- BRM421
- Where
- 2 sites in United States
- Volunteers
- 157 people
- Sponsor
- BRIM Biotechnology Inc.
Sjogren's Disease
Evaluation of Ocular Surface Inflammatory Mediators Effected by Lotemax
The purpose of this study is to evaluate the effects of an anti-inflammatory drug (Lotemax®) on the surface of the eye and tear film (a film that coats the eye which is made up of oil and water).
- Trial name
- NCT02322528
- Testing
- Administration of Lotemax
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of Rochester
Primary Sjögren Syndrome
A Study Evaluating the Effects of GLPG3970 Given as an Oral Treatment for 12 Weeks in Adults With Active Primary Sjögren's Syndrome (pSS)
This is a first exploration of GLPG3970 in participants with active primary Sjogren's Syndrome (pSS) to evaluate the efficacy, safety and tolerability and to determine its pharmacokinetics (PK) profile compared to placebo.
- Trial name
- GLIDER (NCT04700280)
- Testing
- GLPG3970
- Where
- 10 sites in Germany, Greece and 3 more
- Volunteers
- 31 people
- Sponsor
- Lakefront Biotherapeutics NV
Blepharitis, Dry Eye Syndrome
Treatment of Meibomian Gland Dysfunction Prior to Cataract Surgery
The purpose of this pilot feasibility study is to assess whether treating meibomian gland dysfunction (MGD) prior to cataract surgery helps promote meibomian gland function, visual quality and ocular comfort after cataract…
- Trial name
- NCT01808560
- Testing
- LipiFlow Pre-Treatment, LipiFlow Post-treatment
- Where
- 7 sites in United States
- Volunteers
- 34 people
- Sponsor
- TearScience, Inc.